Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2006

View Archived Issues

Phase I data on RC-1291, a ghrelin mimetic targeted for cancer cachexia

AEterna Zentaris report on novel peptidomimetic GnRH antagonist

Pfizer reports on weekly rhGh injection

Barr submits regulatory filings for acquisition of Pliva

Avicena studies ALS-08 combination therapies for ALS

Noopept shows therapeutic potential for Alzheimer's disease

Japanese agreement signed for Zevalin

DL-06001 and DL-06002 studied for symptoms of Parkinson's disease

Phase III study of TH-9507 for HIV-associated lipodystrophy cleared to continue

Phase Ib study investigates Reolysin/radiation therapy in advanced cancers

Novozymes acquires Delta Biotechnology

Sanctura XR reduces overactive bladder symptoms with good tolerability

DMXB-A improves neurocognition in schizophrenia patients

Phase I results encouraging with EKB-569 in advanced cancer patients

Pirfenidone pharmacokinetics assessed in rats, dogs and humans

Intraarticular steroids beneficial in hip osteoarthritis

Cook's Zilver stent approved for vascular use

MabThera approved for rheumatoid arthritis in Europe

European approval for MabThera as maintenance therapy in NHL

Pharmacokinetic profile of Huperzine A prodrug ZT-1 reported

Selective ACAT1 inhibitor shows plaque-stabilizing activity in a mouse model of atherosclerosis

New therapeutic agents for HIV infection disclosed in recent patents

Novel PPAR ligands for dermatological disorders described in recent Galderma patent

New coagulation factor Xa inhibitors prepared and tested

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...